A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

This open-label, multi-center, dose-escalation study will evaluate the safety, pharmacokinetics, and therapeutic activity of RO6895882 in participants with Carcinoembryonic Antigen (CEA)-positive solid tumors who have progressed on the standard of care therapy. The study will be conducted in 3 parts. Part 1 will be a single ascending dose study in single participant cohort at low RO6895882 dose (less than or equal to \[\</=\] 6 milligrams \[mg\]). Part 2 will be a dose-escalation study of RO6895882 monotherapy given every week (qw), every 2 weeks (q2w), and possibly every 3 weeks (q3w). Part 3 will be an expansion phase of the qw, q2w, and possibly q3w at maximum tolerated dose (MTD) (as determined in Part 2). Part 3 will only be conducted if the risk/benefit assessment, as evaluated by the Sponsor and the investigators, is in favor of the participants. Participants will be treated until disease progression, unacceptable toxicity or withdrawal from treatment for other reasons or death for a maximum duration of 24 months.

Key facts

Study ID: NCT02004106
Run by: Hoffmann-La Roche
People needed: 110
Starts: 2013-12-31
Expected to finish: 2016-08-31
Last updated by the study team: 2018-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants with confirmed advanced and/or metastatic solid tumor, with at least one tumor lesion of non-critical location accessible to biopsy who have progressed on the standard of care therapy
Locally confirmed CEA expression in tumor tissue (more than [>] 20 percent (%) of tumor cells staining with at least moderate intensity) or centrally confirmed CEA expression if no archival tumor tissue and fresh biopsy is collected
Radiologically measurable and clinically evaluable disease
Life expectancy of greater than or equal to (>/=) 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
All acute toxic effects of any prior radiotherapy, chemotherapy or surgical procedure must have resolved to Grade </=1, except alopecia (any grade) and Grade 2 peripheral neuropathy
Adequate hematological, liver, and renal function
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women </=2 years after menopause
Participants with Gilbert's syndrome will be eligible for the study. A diagnosis of Gilbert's syndrome will be based on the exclusion of other diseases based on the following criteria: (i) unconjugated hyperbilirubinemia noted on several occasions; (ii) no evidence of hemolysis (normal hemoglobin, reticulocyte count, and Lactate dehydrogenase); (iii) normal liver function tests; (iv) absence of other diseases associated with unconjugated hyperbilirubinemia

You may not qualify if…

History or clinical evidence of central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before screening
Participants with an active second malignancy (other than non-melanoma skin cancer, or cervical carcinoma in situ). Participants who have a history of malignancy are not considered to have an active malignancy if they have completed therapy and are considered by their treating physician to be at less than (<) 30% risk for relapse
Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders and known autoimmune diseases
Uncontrolled hypertension (systolic >150 millimeter of mercury [mmHg] and/or diastolic >100 mmHg), unstable angina, congestive heart failure (CHF) of any New York Heart Association (NYHA) classification, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months of enrollment
Active or uncontrolled infections
Known infection with human immunodeficiency virus (HIV), seropositive status
Positive test results for chronic hepatitis B infection (defined as positive Hepatitis B surface antigen [HBsAg] serology and/or HBcAb status)
Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
Pregnant or breast-feeding women
Known hypersensitivity to any of the components of RO6895882
Concurrent therapy with any other investigational drug
Regular immunosuppressive therapy (that is, for organ transplantation, chronic rheumatologic disease)
Chronic use of steroids (including inhaled) will not be allowed. Concurrent high doses of systemic corticosteroids. High dose is considered as >20 mg of dexamethasone a day (or equivalent) for >7 consecutive days
Radiotherapy within the last 4 weeks before start of study drug treatment with the exception of limited field palliative radiotherapy for bone pain relief

Where it is running

Memorial Sloan Kettering Cancer Center — New York, New York, United States
Rigshospitalet, Onkologisk Klinik — København Ø, Denmark
Helsinki University Central Hospital; Dept of Oncology — Helsinki, Finland
Institut Gustave Roussy; Departement Oncologie Medicale — Villejuif, France
Antoni van Leeuwenhoek Ziekenhuis — Amsterdam, Netherlands
VU MEDISCH CENTRUM; Dept. of Medical Oncology — Amsterdam, Netherlands
Clinica Universitaria de Navarra; Servicio de oncología — Pamplona, Navarre, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia — Barcelona, Spain
CHUV; Departement d'Oncologie — Lausanne, Switzerland
Oxford University Hospitals NHS Trust - Churchill Hospital — Oxford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.